[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@StreetCred2017 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::949761349197864960.png) @StreetCred2017 @StreetCred2018

@StreetCred2018 posts on X about $amgn, $ifrx, approved, $trml the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::949761349197864960/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::949761349197864960/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXXX +52%
- X Months XXXXXX -XX%
- X Year XXXXXXXXX +106%

### Mentions: X [#](/creator/twitter::949761349197864960/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::949761349197864960/c:line/m:posts_active.svg)

- X Week XX -XX%
- X Month XX +38%
- X Months XXX -XX%
- X Year XXX +60%

### Followers: XXX [#](/creator/twitter::949761349197864960/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::949761349197864960/c:line/m:followers.svg)

- X Week XXX no change
- X Month XXX +0.36%
- X Months XXX +13%
- X Year XXX -XXXX%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::949761349197864960/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::949761349197864960/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::949761349197864960/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXX% [finance](/list/finance)  XXXX% [technology brands](/list/technology-brands)  XXXX%

**Social topic influence**
[$amgn](/topic/$amgn) #26, [$ifrx](/topic/$ifrx) #3, [approved](/topic/approved) 1.03%, [$trml](/topic/$trml) 1.03%, [$nov](/topic/$nov) 1.03%, [ra](/topic/ra) 1.03%, [$omda](/topic/$omda) 1.03%, [finance](/topic/finance) 1.03%, [upside](/topic/upside) 1.03%, [$4b](/topic/$4b) XXXX%

**Top accounts mentioned or mentioned by**
[@quick2smile](/creator/undefined) [@o248528307](/creator/undefined) [@3in5saved](/creator/undefined) [@maximusholla](/creator/undefined) [@dogtor01416800](/creator/undefined) [@rdd147](/creator/undefined) [@kobeissiletter](/creator/undefined) [@biovalues](/creator/undefined) [@cdcdirector](/creator/undefined) [@cdcgov](/creator/undefined) [@fdacderdirector](/creator/undefined) [@usdafoodsafety](/creator/undefined) [@billackman](/creator/undefined) [@peterschiff](/creator/undefined) [@realdonaldtrump](/creator/undefined) [@elonmusk](/creator/undefined) [@semodough](/creator/undefined) [@zerohedge](/creator/undefined) [@biotechsanya2](/creator/undefined) [@lawdawg050](/creator/undefined)

**Top assets mentioned**
[Amgen, Inc. (AMGN)](/topic/$amgn) [Tourmaline Bio, Inc. Common Stock (TRML)](/topic/$trml) [Novara Calcio Fan Token (NOV)](/topic/$nov) [Hundred Million (100M)](/topic/$100m)
### Top Social Posts [#](/creator/twitter::949761349197864960/posts)
---
Top posts by engagements in the last XX hours

"@Quick2smile @ANKITSH85153215 Interesting and I think Inflarx did same thing w cSCC At end of the day it (C5a antagonist) may wind up being used in combination w some chemo agent. $AMGN $IFRX #PancreaticCancer needs anything that improves XX% survival rates. Compassionate use"  
[X Link](https://x.com/StreetCred2017/status/1975181788009115894) [@StreetCred2017](/creator/x/StreetCred2017) 2025-10-06T12:50Z XXX followers, XXX engagements


"@ANKITSH85153215 Friday study showing $AMGN c5aR pathway complement system and soc chemo reduced pancreatic cancer tumor 80%. Big for Avacopan already FDA approved AAV. $IFRX best in c5aR class. #PancreaticCancer very low X yr survival 12%"  
[X Link](https://x.com/StreetCred2017/status/1975156347021951437) [@StreetCred2017](/creator/x/StreetCred2017) 2025-10-06T11:09Z XXX followers, XXX engagements


"@BOSSTRADING0 Not a bad deal after cashing ticket on $TRML XX% buyout today from $NOV Also watching new buys RA Capital $IFRX $OMDA"  
[X Link](https://x.com/StreetCred2017/status/1965509399390347330) [@StreetCred2017](/creator/x/StreetCred2017) 2025-09-09T20:15Z XXX followers, XXX engagements


"@Investorclimber @Biotech_AI Gents - any best guess on upside with only X of X showing promise VS both CSU Yes HS -No: or visa versa Guggenheim called 5-10x but seems overly optimistic given need to finance P2b but both wld show pipeline potential. Also partner needed"  
[X Link](https://x.com/StreetCred2017/status/1978425820487069859) [@StreetCred2017](/creator/x/StreetCred2017) 2025-10-15T11:40Z XXX followers, XX engagements


"@biotechsanya2 Also avacopan is approved for AAV so not exactly a failure for $AMGN but assume youre talking about the P1 Inflarx comparison of INF904 v avacopan"  
[X Link](https://x.com/StreetCred2017/status/1978589499119604212) [@StreetCred2017](/creator/x/StreetCred2017) 2025-10-15T22:31Z XXX followers, XXX engagements


"$AMGN Breaking: Avacopan seen blocking pancreatic cancer tumors over XX% when combined with gemcitabine/nab-paclitaxel (standard PDAC chemo) XX% Avacopan motherly only - looks like way bigger market for C5aR inhibitor market than just AAV supporting $4b buyout $CCXI $IFRX still at a whopping $100m In vivo CCX168 monotherapy reduced tumor volume by XX% (p0.01); combining it with gemcitabine/nab-paclitaxel (standard PDAC chemo) and immune checkpoint inhibitors (pembrolizumab/ipilimumab) achieved the strongest effectsup to XX% tumor reduction increased CD8+ T-cell infiltration (p0.01) and"  
[X Link](https://x.com/StreetCred2017/status/1974984833693589821) [@StreetCred2017](/creator/x/StreetCred2017) 2025-10-05T23:47Z XXX followers, XXX engagements


"@biotechsanya2 Not sure if this helps comparing $AMGN avacopan v INF904 $IFRX"  
[X Link](https://x.com/StreetCred2017/status/1978605196461695371) [@StreetCred2017](/creator/x/StreetCred2017) 2025-10-15T23:33Z XXX followers, XXX engagements